Qianjin Pharmaceutical’s warning announcement on stock trading risks

Securities code: 600479 Securities abbreviation: Qianjin Pharmaceutical Announcement number: 2026-031

Zhuzhou Qianjin Pharmaceutical Co., Ltd.

Cautionary announcement on stock trading risks

The company's board of directors and all directors guarantee that the contents of this announcement do not contain any false records, misleading statements or major omissions, and assume legal responsibility for the authenticity, accuracy and completeness of its contents.

Important content reminder:

 The stock of Zhuzhou Qianjin Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company") closed at the daily limit price for three consecutive trading days on August 26, August 27, and August 28, 2026, with a cumulative increase of 33.03%, which was significantly higher than the 3.57% increase of the Traditional Chinese Medicine II (Shenwan) Industry Index during the same period. The company has disclosed the "Qianjin Pharmaceutical Announcement on Abnormal Stock Trading Fluctuations" on August 28, 2026 (Announcement Number: 2026-030). On August 28, 2026, the company's stock price reached the daily limit again, and the company's stock price has now increased significantly.

 The company’s main business has not changed, and there is no major undisclosed information that should be disclosed. Part of the company's performance growth in the first half of 2026 comes from the acquisition of 28.92% equity in Hunan Qianjin Xiangjiang Pharmaceutical Co., Ltd. and 68% equity in Hunan Qianjin Xieli Pharmaceutical Co., Ltd., which will be included in the consolidated statements according to the new shareholding ratio. This acquisition will increase the company's net profit attributable to shareholders of listed companies in the first half of 2026 by 39.8695 million yuan, accounting for 22.05% of the company's net profits attributable to shareholders of listed companies in the first half of 2026.

 The company urges investors to pay attention to secondary market transaction risks, make rational decisions, and invest prudently.

In view of the recent large fluctuations in the company's stock price, the company's relevant matters and risks are explained as follows:

1. Secondary market transaction risks

On August 28, 2026, the company’s stock reached its daily limit again. Since August 26, 2026, the company's stock has reached the daily limit for three consecutive trading days, with a cumulative increase of 33.03%. According to data from Oriental Finance's Choice intelligent financial terminal, the company's stock price increase in the past three trading days was significantly higher than the 3.57% increase in the Traditional Chinese Medicine II (Shenwan) industry index during the same period. At present, the company's stock price has increased significantly. Investors are kindly requested to pay attention to the risks of secondary market transactions, make rational decisions, and invest prudently.

2. The company’s production and operations

The company's main business has not changed, and there is no major undisclosed information that should be disclosed. Part of the company's performance growth in the first half of 2026 comes from the acquisition of 28.92% equity in Hunan Qianjin Xiangjiang Pharmaceutical Co., Ltd. and 68% equity in Hunan Qianjin Xieli Pharmaceutical Co., Ltd., which will be included in the consolidated statements according to the new shareholding ratio. This acquisition will increase the company's net profit attributable to shareholders of listed companies in the first half of 2026 by 39.8695 million yuan, accounting for 22.05% of the company's net profits attributable to shareholders of listed companies in the first half of 2026. At present, the company's production and operation are in normal condition, there have been no major adjustments to the market environment and industry policies, and there have been no major changes to the internal and external operating environment and main business. Investors are kindly requested to pay attention to the risks of secondary market transactions, make rational decisions, and invest prudently.

3. Major matters

Up to now, the company, controlling shareholders and actual controllers have not planned any major asset reorganization, share issuance, major transaction matters, business reorganization, share repurchase, equity incentives, bankruptcy reorganization, major business cooperation, introduction of strategic investors and other major matters involving the company.

4. Media reports, market rumors, and hot concepts

As of now, the company has found no media reports or market rumors that may have a significant impact on the company's stock trading price, nor does it involve other hot concept matters; except for the information disclosed by the company, there is no other major information that should be disclosed but has not been disclosed.

The company solemnly reminds investors that relevant company information is subject to the relevant announcements published by the company on the Shanghai Stock Exchange website (www.sse.com.cn) and the designated information disclosure media "China Securities Journal", "Shanghai Securities News", "Securities Daily" and "Securities Times". Investors are kindly requested to invest rationally and pay attention to investment risks.

Announcement is hereby made.

Board of Directors of Zhuzhou Qianjin Pharmaceutical Co., Ltd.

August 29, 2026